Ponatinib - ARIAD Pharmaceuticals

Drug Profile

Ponatinib - ARIAD Pharmaceuticals

Alternative Names: AP-24534; AP24534 HCl; AP24534 hydrochloride; AP24534-HCL; Iclusig; Ponatinib hydrochloride

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ARIAD Pharmaceuticals
  • Developer ARIAD Pharmaceuticals; Dana-Farber Cancer Institute; Massachusetts General Hospital; Mayo Clinic; National Cancer Institute (USA); Otsuka Pharmaceutical; University of Birmingham; University of Colorado at Denver
  • Class Antineoplastics; Benzamides; Imidazoles; Piperazines; Pyridazines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Fibroblast growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Acute myeloid leukaemia; Biliary cancer; Gastrointestinal stromal tumours; Lung cancer; Squamous cell cancer; Thyroid cancer
  • No development reported Solid tumours

Most Recent Events

  • 08 Feb 2018 Takeda initiates enrolment in a phase II trial in Acute lymphoblastic leukaemia (Second-line therapy or greater, First-line therapy, Combination therapy) in USA (PO) (NCT03147612)
  • 29 Nov 2017 Ariad Pharmaceuticals and MD Anderson Cancer Center initiates enrolment in a phase II trial for Acute lymphoblastic leukaemia (Second-line therapy or greater, In adults, In the elderly, Combination therapy) in USA (PO) (NCT03263572)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top